Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Inventors

Han, Sangdon • ZHU, Yunfei • Kim, Sun Hee • Zhao, Jian

Assignees

Crinetics Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10766877-B2

Patent

Publication Date

2020-09-08

Expiration Date


Abstract

Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.

Core Innovation

The disclosure provides substituted compounds of Formula (I)–(IX), particularly Formula (IX), or pharmaceutically acceptable salts or solvates thereof, wherein V is N and X1 is CR6. These compounds function as melanocortin receptor modulators, specifically MC2R antagonists, featuring scaffolds with defined substituents encompassing hydrogen, halogen, alkyl, fluoroalkyl, heteroalkyl, carbocycle, heterocycle, aryl, phenyl, heteroaryl, piperazine benzamides, and bipyridine carboxamides.

The embodiments encompass stereoisomers, cis/trans variants, isotopically labeled compounds, prodrugs, active metabolites, and representative parenteral, oral, or topical pharmaceutical compositions. The compounds and compositions are directed to modulating melanocortin subtype-2 receptor activity and treating Cushing's syndrome, with an hMC2R binding screening result table reporting Ki values under 10 nM and between 10–100 nM, while the background problem is not explicitly described.

Claims Coverage

The provided claims identify one independent claim, claim 1, comprising four inventive features directed to a compound genus of Formula (IX) and its pharmaceutically acceptable salts or solvates.

Formula (IX) compounds

Claim 1 covers a compound of Formula (IX), or a pharmaceutically acceptable salt or solvate thereof, wherein V is N.

Defined scaffold and substituent alternatives

The claim specifies X1 as CR6, with R6 being H or F, and defines alternatives for scaffold substituents Ra, Rb, Rc, RB, Rd, Re, and Rf, including hydrogen, halogen, alkyl, fluoroalkyl, heteroalkyl, carbocycle, heterocycle, phenyl, aryl, and heteroaryl groups.

Defined R2, R3, and R4 groups

The claim specifies that R2 and R3 are hydrogen, or are taken together with their attached carbon atom to form —C(=O)—, and defines R4 as selected from hydrogen, alkyl, monocyclic carbocycle or heterocycle, and alkyl-linked carbocycle or heterocycle groups.

Substituent definitions for R7, R8, R9, and R10

The claim defines permitted groups for R7, R8, R9, and R10, including specified alkyl, cycloalkyl, aryl, heteroaryl, and functional-group alternatives.

The independent claim defines the Formula (IX) compound genus, its specified scaffold and substituent alternatives, and pharmaceutically acceptable salts and solvates, while dependent claims recite specific compounds, pharmaceutical compositions, and MC2R-related treatment methods.

Stated Advantages

Not explicitly described in patent.

Documented Applications

A pharmaceutical composition comprising a Formula (IX) compound, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

Modulating melanocortin subtype-2 receptor (MC2R) activity in a mammal using a claimed compound, or a pharmaceutically acceptable salt or solvate thereof.

Treating Cushing’s syndrome and conditions or diseases associated with MC2R activity using a claimed compound, or a pharmaceutically acceptable salt or solvate thereof.

Representative parenteral, oral, and topical dosage formulations.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.